Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications

Future Medicinal Chemistry

Volumn 1, Issue 3, 2009, Pages 515-528

  Zheng, Fang ^a   Zhan, Chang Guo ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CHOLINESTERASE; COCAINE;

CATALYSIS; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

BINDING SITES; BUTYRYLCHOLINESTERASE; CARBOXYLIC ESTER HYDROLASES; COCAINE; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 77953470383     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.20     Document Type: Review

References (54)

1. Zhan CG. Modeling reaction mechanism of cocaine hydrolysis and rational drug design for therapeutic treatment of cocaine abuse. In: Topics in Heterocyclic Drugs (Volume 4). Gupta SP (Ed.). Springer-Verlag, Heidelberg, Germany, 107-159 (2006).
2. Landry DW, Yang GX. Anticocaine catalytic antibodies: a novel approach to the problem of addiction. J. Addict. Dis. 16, 1-17 (1997).
3. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad. Med. J. 83, 389-394 (2007).
4. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48, 159-165 (1997).
5. Redish AD. Addiction as a computational process gone awry. Science 306, 1944-1947 (2004).
6. Huang X, Zhan CG. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys. J. 93, 3627-3639 (2007).
7. Beuming T, Kniazeff J, Bergmann ML et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 11, 780-789 (2008).
8. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 64, 1547-1573 (2004).
9. Landry DW, Zhao K, Yang GXQ, Glickman M, Georgiadis TM. Antibody catalyzed degradation of cocaine. Science 259, 1899-1901 (1993).
10. Zhan CG, Deng SX, Skiba JG et al. First-principle studies of intermolecular and intramolecular catalysis of protonated cocaine. J. Comput. Chem. 26, 980-986 (2005).
11. Zheng F, Zhan CG. Structure-andmechanism- based design and discovery of therapeutics for cocaine overdose. Org. Biomol. Chem. 6, 836-843 (2008).
12. Larsen NA, Turner JM, Stevens J et al. Crystal structure of a bacterial cocaine esterase. Nat. Struct. Biol. 9, 17-21 (2002).
13. Cooper ZD, Narasimhan D, Sunahara RK et al. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 70, 1885-1891 (2006).
14. Ko MC, Bowen LD, Narasimhan D et al. Cocaine esterase: interactions with cocaine and immune responses in mice. J. Pharmacol. Exp. Ther. 320, 926-933 (2007).
15. Zheng F, Zhan CG. Rational design of an enzyme mutant for anticocaine therapeutics. J. Comput. Aided Mol. Des. 22, 661-671 (2008).
16. Lehmann M, Wyss M. Engineering proteins for thermostability: the use of sequence alignments versus rational design and directed evolution. Curr. Opin. Biotechnol. 12, 371-375 (2001).
17. Korkegian A, Black ME, Baker D, Stoddard BL. Computational thermostabilization of an enzyme. Science 308, 857-860 (2005).
18. Dantas G, Kuhlman B, Callender D, Wong M, Baker D. A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. J. Mol. Biol. 332, 449-460 (2003).
19. Looger LL, Dwyer MA, Smith JJ, Hellinga HW. Computational design of receptor and sensor proteins with novel functions. Nature 423, 185-190 (2003).
20. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D. Design of a novel globular protein fold with atomic-level accuracy. Science 302, 1364-1368 (2003).
21. Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc. Natl Acad. Sci. USA 97, 10383-10388 (2000).
22. Gao D, Narasimhan DL, Macdonald J et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 75, 318-323 (2009).
23. Corchado JC, Coitino EL, Chuang YY, Fast PL, Truhlar DG. Interpolated vibrational transition-state theory by mapping. J. Phys. Chem. A 102, 2424-2438 (1998).
24. Gao D, Zhan CG. Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins 62, 99-110 (2006).
25. Gao D, Zhan CG. Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases. J. Phys. Chem. B 109, 23070-23076 (2005).
26. Gao D, Cho H, Yang W et al. Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew. Chem. Int. Ed. Engl. 45, 653-657 (2006).
27. Zhan CG, Zheng F, Landry DW. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J. Am. Chem. Soc. 125, 2462-2474 (2003).
28. Zhan CG, Gao D. Catalytic mechanism and energy barriers for butyrylcholinesterasecatalyzed hydrolysis of cocaine. Biophys. J. 89, 3863-3872 (2005).
29. Hamza A, Cho H, Tai HH, Zhan CG. Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J. Phys. Chem. B 109, 4776-4782 (2005).
30. Sun H, Yazal JE, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase: engineering effective butyrylcholinesterase mutants for cocaine detoxication. J. Biol. Chem. 276, 9330-9336 (2005).
31. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol. 67, 204-211 (2001).
32. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62, 220-224 (2002).
33. Pan Y, Gao D, Yang W et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl. Acad. Sci. USA 102, 16656-16661 (2005).
34. Pan Y, Gao D, Yang W, Cho H, Zhan CG. Free energy perturbation (FEP) simulation on the transition-states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J. Am. Chem. Soc. 129, 13537-13543 (2007).
35. Zheng F, Yang W, Ko MC et al. Most efficient cocaine hydrolase designed by virtual screening of transition States. J. Am. Chem. Soc. 130, 12148-12155 (2008).
36. Pan Y, Gao D, Zhan CG. Modeling the catalysis of anticocaine catalytic antibody: competing reaction pathways and free energy barriers. J. Am. Chem. Soc. 130, 5140-5149 (2008).
37. Yang W, Pan Y, Zheng F, Cho H, Tai HH, Zhan CG. Free energy perturbation (FEP) simulation on transition states and design of high-activity mutants of human butyrylcholinesterase for accelerating cocaine metabolism. Biophys. J. 96, 1931-1993 (2009).
38. Brimijoin S, Gao Y, Anker JJ et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33, 2715-2725 (2008).
39. Pancook JD, Pecht G, Ader M, Mosko M, Lockridge O, Watkins JD. Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J. 17, A565 (2003).
40. Poole AM, Ranganathan R. Knowledge-based potentials in protein design. Curr. Opin. Struct. Biol. 16, 508-513 (2006).
41. Russ WP, Lowery DM, Mishra P, Yaffe MB, Ranganathan R. Natural-like function in artificial WW domains. Nature 437, 579-583 (2005).
42. Alvizo O, Mayo SL. Evaluating and optimizing computational protein design force fields using fixed composition-based negative design. Proc. Natl Acad. Sci. USA 105, 12242-12247 (2008).
43. Alvizo O, Allen BD, Mayo SL. Computational protein design promises to revolutionize protein engineering. BioTechniques 42, 31-39 (2007).
44. Benson DE, Wisz MS, Liu W, Hellinga HW. Construction of a novel redox protein by rational design: conversion of a disulfide bridge into a mononuclear iron-sulfur center. Biochemistry 37, 7070-7076 (1998).
45. Benson DE, Conrad DW, de Lorimier RM, Trammell SA, Hellinga HW. Design of bioelectronic interfaces by exploiting hinge-bending motions in proteins. Science 293, 1641-1644 (2001).
46. Looger LL, Dwyer MA, Smith JJ, Hellinga HW. Computational design of receptor and sensor proteins with novel functions. Nature 423, 185-190 (2003).
47. Allert M, Rizk SS, Looger LL, Hellinga HW. Computational design of receptors for an organophosphate surrogate of the nerve agent soman. Proc. Natl Acad. Sci. USA 101, 7907-7912 (2004).
48. Huang YJ, Huang Y, Baldassarre H et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl Acad. Sci. USA 104, 13603-13608 (2007).
49. Huang YJ, Lundy PM, Lazaris A et al. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol. 8, 50 (2008).
50. Barr AM, Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci. Biobehav. Rev. 29. 675-706 (2005).
51. Keating GM, Simpson D. Agalsidase β: a review of its use in the management of Fabry disease. Drugs 67, 435-455 (2007).
52. Clarke JTR. A Clinical Guide to Inherited Metabolic Diseases (2nd Edition). Cambridge University Press, Cambridge, UK (2007).
53. Jiang L, Althoff EA, Clemente FR et al. De novo computational design of retro-aldol enzymes. Science 319, 1387-1391 (2008).
54. Röthlisberger D, Khersonsky O, Wollacott AM et al. Kemp elimination catalysts by computational enzyme design. Nature 453, 190-195 (2008).